|
|
BCG vaccine vector |
|
Vaxvec ID |
12 |
|
Vaccine Vector Name |
BCG vaccine vector |
|
Alternative Names |
Bacillus Calmette-Guerin vaccine vector; rBCG vaccine vector |
|
Vector VO ID |
VO_0001023
|
|
Function |
BCG is commonly used as a human vaccine against tuberculosis. It is also often used as a bacterial vaccine vector against many diseases, such as malaria and HIV (Kanekiyo et al., 2005). |
|
Advantage |
Relatively inexpensive to produce; easy to administer; induces strong cellular immune responses (Kanekiyo et al., 2005). Recombinant BCG is able to produce and secrete antigens. It may also be used against allergic diseases (Kumar et al., 1999). |
|
Disadvantage |
Induction of persistent tuberculin positivity in vaccinated individuals; necrotic reactions in those individuals with the Koch phenomenon (Kumar et al., 1999). |
|
Storage |
Stored by freeze-drying, but stabilization methods need improvement. (Gheorghiu et al., 1996) |
|
Safety |
Live, attenuated. As a human tuberculosis vaccine, its safety has been proven. |
| Related Vaccine(s) |
|
| References |
Gheorghiu et al., 1996: Gheorghiu M, Lagranderie M, Balazuc AM. Stabilisation of BCG vaccines. Developments in biological standardization. 1996; 87; 251-261. [PubMed: 8854025].
Kanekiyo et al., 2005: Kanekiyo M, Matsuo K, Hamatake M, Hamano T, Ohsu T, Matsumoto S, Yamada T, Yamazaki S, Hasegawa A, Yamamoto N, Honda M. Mycobacterial codon optimization enhances antigen expression and virus-specific immune responses in recombinant Mycobacterium bovis bacille Calmette-Guérin expressing human immunodeficiency virus type 1 Gag. Journal of virology. 2005; 79(14); 8716-8723. [PubMed: 15994765].
Kumar et al., 1999: Kumar M, Behera AK, Matsuse H, Lockey RF, Mohapatra SS. A recombinant BCG vaccine generates a Th1-like response and inhibits IgE synthesis in BALB/c mice. Immunology. 1999; 97(3); 515-521. [PubMed: 10447775].
|
|
